[1]
|
Eslam, M., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209. https://doi.org/10.1016/j.jhep.2020.03.039
|
[2]
|
Younossi, Z., et al. (2018) Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention. Nature Reviews Gastroenterology & Hepatology, 15, 11-20. https://doi.org/10.1038/nrgastro.2017.109
|
[3]
|
Younossi, Z., et al. (2019) Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 69, 2672-2682. https://doi.org/10.1002/hep.30251
|
[4]
|
Estes, C., et al. (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016-2030. Journal of Hepa-tology, 69, 896-904.
https://doi.org/10.1016/j.jhep.2018.05.036
|
[5]
|
Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[6]
|
Cai, J., et al. (2021) Advances in the Epidemiology of Pancreatic Cancer: Trends, Risk Factors, Screening, and Prognosis. Cancer Letters, 520, 1-11. https://doi.org/10.1016/j.canlet.2021.06.027
|
[7]
|
Hu, J.X., et al. (2021) Pancreatic Cancer: A Review of Epidemi-ology, Trend, and Risk Factors. World Journal of Gastroenterology, 27, 4298-4321. https://doi.org/10.3748/wjg.v27.i27.4298
|
[8]
|
Zhao, Z. and Liu, W. (2020) Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. Technology in Cancer Research & Treatment. https://doi.org/10.1177/1533033820962117
|
[9]
|
Byrne, C.D. and Targher, G. (2015) NAFLD: A Multisystem Disease. Journal of Hepatology, 62, S47-S64.
https://doi.org/10.1016/j.jhep.2014.12.012
|
[10]
|
Diehl, A.M. and Day, C. (2017) Cause, Pathogenesis, and Treat-ment of Nonalcoholic Steatohepatitis. The New England Journal of Medicine, 377, 2063-2072. https://doi.org/10.1056/NEJMra1503519
|
[11]
|
Mitsala, A., et al. (2022) Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep’s Clothing? Current Oncology, 29, 4478-4510. https://doi.org/10.3390/curroncol29070356
|
[12]
|
Rezende, A.Q.M., et al. (2021) Is There a Link between Non-Alcoholic Fatty Liver Disease Aspects and Pancreatic Cancer? Results of a Case-Matched Study. Revista do Colégio Brasileiro de Cirurgiões, 48, e20202913.
https://doi.org/10.1590/0100-6991e-20202913
|
[13]
|
Allen, A.M., et al. (2019) The Risk of Incident Extrahepatic Cancers Is Higher in Non-Alcoholic Fatty Liver Disease than Obesity—A Longitudinal Cohort Study. Journal of Hepa-tology, 71, 1229-1236.
https://doi.org/10.1016/j.jhep.2019.08.018
|
[14]
|
Park, J.H., et al. (2022) Increased Risk of Pancreatic Cancer in In-dividuals with Non-Alcoholic Fatty Liver Disease. Scientific Reports, 12, Article No. 10681. https://doi.org/10.1038/s41598-022-14856-w
|
[15]
|
Simon, T.G., et al. (2021) Cancer Risk in Patients with Biop-sy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Hepatology, 74, 2410-2423. https://doi.org/10.1002/hep.31845
|
[16]
|
Kim, G.A., et al. (2017) Association between Non-Alcoholic Fatty Liver Disease and Cancer Incidence Rate. Journal of Hepatology.
|
[17]
|
Alessandro Mantovani, M., Petracca, G., Beatrice, G., et al. (2022) Non‐Alcoholic Fatty Liver Disease and Increased Risk of Incident Extra‐Hepatic Cancers: A Meta‐Analysis of Observational Cohort Studies. Gut, 71, 778-788.
https://doi.org/10.1136/gutjnl-2021-324191
|
[18]
|
Colotta, F., et al. (2009) Cancer-Related Inflammation, the Sev-enth Hallmark of Cancer: Links to Genetic Instability. Carcinogenesis, 30, 1073-1081. https://doi.org/10.1093/carcin/bgp127
|
[19]
|
Ren, R., et al. (2019) Inflammation Promotes Progression of Pancreatic Cancer through WNT/beta-Catenin Pathway- Dependent Manner. Pancreas, 48, 1003-1014. https://doi.org/10.1097/MPA.0000000000001386
|
[20]
|
Zhang, Y., et al. (2013) Canonical WNT Signaling Is Re-quired for Pancreatic Carcinogenesis. Cancer Research, 73, 4909-4922. https://doi.org/10.1158/0008-5472.CAN-12-4384
|
[21]
|
Tao, M., et al. (2016) Inflammatory Stimuli Promote Growth and Invasion of Pancreatic Cancer Cells through NF- kappaB Pathway Dependent Repression of PP2Ac. Cell Cycle, 15, 381-393.
https://doi.org/10.1080/15384101.2015.1127468
|
[22]
|
Alberto Villanueva, C.G., Paules, A.B., Vicente, M., et al. (1998) Disruption of the Antiproliferative TGF-b Signaling Pathways in Human Pancreatic Cancer Cells. Oncogene, 17, 1969-1978. https://doi.org/10.1038/sj.onc.1202118
|
[23]
|
Feng, H.Y. and Chen, Y.C. (2016) Role of Bile Acids in Carcinogenesis of Pancreatic Cancer: An Old Topic with New Perspective. World Journal of Gastroenterology, 22, 7463-7477. https://doi.org/10.3748/wjg.v22.i33.7463
|
[24]
|
Režen, T., Rozman, D., Kovács, T., Kovács, P., Sipos, A., Bai, P. and Mikó, E. (2022) The Role of Bile Acids in Carcinogenesis. Cellular and Molecular Life Sciences, 79, 243. https://doi.org/10.1007/s00018-022-04278-2
|
[25]
|
Leung, C., et al. (2016) The Role of the Gut Microbiota in NAFLD. Nature Reviews Gastroenterology & Hepatology, 13, 412-425. https://doi.org/10.1038/nrgastro.2016.85
|
[26]
|
Wei, M.Y., et al. (2019) The Microbiota and Microbiome in Pancre-atic Cancer: More Influential than Expected. Molecular Cancer, 18, 97. https://doi.org/10.1186/s12943-019-1008-0
|
[27]
|
Paul, J. and Shihaz, A.V.H. (2020) Pancreatic Steatosis: A New Diagnosis and Therapeutic Challenge in Gastroenterology. Arquivos de Gastroenterologia, 57, 216-220. https://doi.org/10.1590/s0004-2803.202000000-27
|
[28]
|
Chang, M.L. (2022) Fatty Pancreas-Centered Metabolic Basis of Pancreatic Adenocarcinoma: From Obesity, Diabetes and Pancreatitis to Oncogenesis. Biomedicines, 10, 692. https://doi.org/10.3390/biomedicines10030692
|
[29]
|
Bugianesi, E., et al. (2010) Insulin Resistance in Nonalcoholic Fatty Liver Disease. Current Pharmaceutical Design, 16, 1941-1951. https://doi.org/10.2174/138161210791208875
|